세라 프로그노스틱스(SERA)는 NASDAQ에 상장된 Healthcare · Medical Devices 기업입니다. 현재가 $1.96 (-2.49%), 시가총액 $0.07B, 52주 범위 $1.49 ~ $4.09.
Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation. It is also involved in the development of a pipeline of novel blood-based biomarker tests and predictive analytic products and services for pregnancy related conditions, such as time-to-birth, predictive analytics product, pregnancy risk prediction panel, preeclampsia, and fetal growth restriction. The company was incorporated in 2008 and is headquartere
세라 프로그노스틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.
세라 프로그노스틱스의 현재 주가는 $1.96 (-2.49%)입니다. BlackQuant에서 실시간 시세와 차트를 확인할 수 있습니다.
세라 프로그노스틱스의 시가총액은 약 $0.07B입니다.
Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company d